Compare Inovio Pharmaceuticals Inc (INO) vs Boston Beer Company Inc (SAM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Boston Beer Company Inc — how do they compare? Inovio Pharmaceuticals Inc trades at $1.15 (market cap $112.19M), while Boston Beer Company Inc trades at $169.87 (market cap $1.76B). The key difference: Boston Beer Company Inc is far larger — about 15.7× Inovio Pharmaceuticals Inc's market cap, and Inovio Pharmaceuticals Inc is trading nearer its 52-week high, Boston Beer Company Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and Boston Beer Company Inc for 59 Days on average.
| INO | SAM | |
|---|---|---|
Market Cap | $112.19M | $1.76B |
Volume | 3,201,278 | 264,496 |
Sector | Health | Consumer Staples |
52-Week High | $2.65 | $260.05 |
52-Week Low | $0.66 | $161.08 |
Typical Hold Time | 43 Days | 59 Days |
Enterprise Value | $83.51M | $1.53B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.15, down 0.43% on the day, with a bearish technical signal from moving averages and oscillators. The company shows consistent quarterly earnings beats but operates at significant losses with a -130,000% net income margin and negative cash flow. Key catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, with analyst consensus leaning bullish at a $2.75 price target.
The investment case hinges on FDA approval of INO-3107, offering substantial upside from current levels. However, persistent cash burn, minimal revenue, and high valuation multiples relative to sales pose significant risks. Investors face binary outcomes driven by regulatory decisions and commercialization execution.
Boston Beer Company (SAM) trades at $170.53, up 1.41% with a bullish technical signal despite recent earnings misses. The stock shows mixed fundamentals with a P/E of 22.66 and negative net margin of -3.64%, though operating cash flow remains strong at $270M. Recent news highlights brand innovation including new cocktail products and marketing partnerships, while analyst consensus leans heavily toward Hold with a $204.44 price target.
SAM faces headwinds from volume declines and cost pressures, but brand investments and new product launches offer growth potential. The stock trades near key support at $169 with institutional interest increasing. Upside depends on successful innovation execution, while downside risks include persistent margin pressure and competitive threats in the beverage sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Boston Beer Company Inc
Boston Beer is a leader in U.S. high-end malt beverages and adjacent categories, with strong positions in craft beer, hard cider, and hard seltzer. The firm sells an array of flavor variants and package sizes, predominantly centered around four priority brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly Hard Seltzer. Its drinks are produced in both company-owned breweries as well as through third-party contract arrangements, and while the company primarily goes to market through independent wholesalers (as mandated by law), it operates a fairly large salesforce to induce demand across the value chain (distributors, retailers, and drinkers). The preponderance of revenue is generated domestically.
Read more on SAM →
